Brief Review of A Randomized Controlled Trial of Liraglutide in Adolescent Obesity— Kelly 2020

This is a brief audio review. In the article A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity published, 2020 by Kelly and Colleagues, The outcomes and key points are as noted: Adolescent patients taking liraglutide for obesity benefit from taking liraglutide seeing a reduction in Body Mass Index. Change in body mass index standard deviation score at 56 weeks was -0.23 +/- 0.05, compared to placebo, the estimated treatment difference was -0.22, 95% CI -0.36 to -0.08, P=0.002. This was a Randomized controlled trial, multicenter, double blinded with 251 patients who were patients who are adolescents with obesity and poor response to lifestyle therapy alone.

Kelly AS, Auerbach P, Barrientos-Perez M, Gies I, Hale PM, Marcus C, Mastrandrea LD, Prabhu N, Arslanian S; NN8022-4180 Trial Investigators. A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity. N Engl J Med. 2020 May 28;382(22):2117-2128. doi: 10.1056/NEJMoa1916038. Epub 2020 Mar 31. PMID: 32233338.